Your session is about to expire
← Back to Search
Erenumab for Post-Traumatic Headache
Study Summary
This trial is looking into whether erenumab is an effective treatment for post-traumatic headache (PTH) caused by mild traumatic brain injury (mTBI).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 4 trial • 701 Patients • NCT04084314Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still room for participants in this investigation?
"Correct. The clinical trial registry confirms that recruitment for this medical study, which was first shared on April 1st 2021, is ongoing. Approximately 112 patients need to be enrolled from 3 distinct sites."
Does this research endeavor represent a pioneering effort for its field?
"Currently, there are 18 trials in progress for erenumab that span 32 countries and 178 cities. The first clinical trial of this drug was conducted by Amgen back in 2019 with 456 participants; since then, a total of 18334 studies have been completed, achieving Phase 3 approval status."
How many participants are currently enrolled in this experiment?
"Yes, according to clinicaltrials.gov this trial still welcomes new participants. It was initially published on April 1st 2021 and last modified on March 11th 2022. A total of 112 patients will be enrolled from 3 distinct sites."
Is it possible for me to join this research endeavor?
"To qualify for this medical research, potential participants must have cervicogenic headache and be aged 18-70. A total of 112 volunteers are being enrolled in the trial."
Could you illustrate the history of research regarding Erenumab?
"Presently, 18 clinical trials examining Erenumab are in motion with 3 of those reaching the third phase. While there is a concentrated focus on Scottsdale, Arizona for this investigation, 548 different medical centres across the nation are taking part."
Has the FDA accepted Erenumab for therapeutic use?
"There is preliminary evidence indicating the safety of Erenumab, and thus it earned a score of 2. However there has yet to be any definitive proof that this drug is effective in humans."
Is enrollment for this research open to minors?
"This clinical study only accepts patients aged between 18 and 70. There are 21 studies specially tailored to those under the age of majority, while 101 trials focus on individuals over 65 years old."
Share this study with friends
Copy Link
Messenger